Medical Letter on the CDC & FDA
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC & FDA
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Dermatology
Agreements for expanded collaboration on psoriasis products in U.S. announced
October 23rd, 2005
LEO Pharma and U.S.-based Warner Chilcott have extended their co-operation to include the full LEO Pharma portfolio of present and future psoriasis treatments. Warner Chilcott is presently marketing Dovonex under a co-promotion deal with Bristol-Myers Squibb Company (BMS) and is currently preparing for the launch of Dovobet in the first half of 2006. LEO Pharma submitted a new drug application to the U.S. Food and Drug Administration (FDA) in March 2005. Subject to approval by the FDA, Warner Chilcott expects to initiate marketing of Dovobet in the second quarter of 2006. The extension of the co-operation also means that Warner Chilcott will have...
Source: Medical Letter on the CDC & FDA (2005-10-23)
|
